Genus Claims

In patent law, a genus claim covers an entire category of inventions, while a species claim covers a specific member of that category: GENUS: the broader category — 'a compound of formula R-X-Y, where R is an alkyl group'; this covers every compound with that formula regardless of what the specific alkyl group is; SPECIES: a specific member — 'methyl-X-Y' or 'ethyl-X-Y' — a particular compound with a specific alkyl group; ANALOGY: genus = 'a chair with four legs and a back' (covers all such chairs); species = 'a Windsor chair with four turned oak legs'; IMPORTANCE: a genus claim is valuable because it provides a wide scope of protection — competitors cannot simply substitute one compound for another to avoid infringement; PHARMACEUTICAL AND BIOTECH CONTEXT: drug developers draft genus claims covering entire chemical series or families of biological molecules; if a competitor later finds a specific compound that works better, the genus claim covers it; MARKUSH GROUP: a common genus claim format in chemistry; lists specific alternatives: 'wherein R is selected from the group consisting of methyl, ethyl, propyl, and phenyl'; covers each member of the group; VALUE OF GENUS vs. SPECIES: a genus claim is far more valuable than multiple species claims if it is valid; one genus claim that survives invalidity attacks is worth hundreds of species claims covering individual members; BUT: a genus claim that is invalidated (for lack of enablement or written description) leaves the patent with only species claims as fallback — which are easily designed around.

The enablement requirement (35 U.S.C. § 112(a)) demands that the specification teach a POSITA how to make and use the claimed invention without undue experimentation — for genus claims, this is extremely demanding: PRE-AMGEN STANDARD: courts applied the Wands 8-factor test (In re Wands, Fed. Cir. 1988) to determine whether undue experimentation was required: (1) quantity of experimentation necessary; (2) amount of direction or guidance in the specification; (3) presence or absence of working examples; (4) nature of the invention; (5) state of the prior art; (6) relative skill of those in the art; (7) predictability of the art; (8) breadth of the claims; AMGEN INC. v. SANOFI (S.Ct. 2023): THE LANDMARK GENUS CLAIM CASE: facts: Amgen claimed all antibodies that bind to a specific location on the PCSK9 protein and block its activity (a functional genus covering potentially millions of antibody variants); Amgen's specification disclosed only 26 specific antibodies with full amino acid sequences and a 'roadmap' methodology for finding additional antibodies; ISSUE: does the specification enable POSITA to make and use all claimed antibodies without undue experimentation?; HOLDING: NO — the specification did not enable the full scope of the genus claim; COURT REASONING: 'if a patent claims an entire class of compositions, the specification must enable a person skilled in the art to make and use the entire class'; disclosing 26 examples out of potentially millions of antibody variants is not enough to enable the full genus; telling POSITA to 'engage in research programs' to discover the rest is not enablement — it's asking them to do the inventor's job; IMPACT: dramatically raised the bar for functional genus claims in pharma and biotech; functional claims that define a genus by what it does (inhibits PCSK9) rather than what it structurally is require extensive specification support.

The written description requirement (35 U.S.C. § 112(a)) is separate from enablement and requires that the specification demonstrate the inventor actually 'possessed' the claimed invention at the time of filing: WRITTEN DESCRIPTION FOR GENUS CLAIMS: a patent claiming a genus must demonstrate possession of the full genus, not just a few species; the specification must 'describe the genus with sufficient specificity to show possession of the full scope'; ARIAD PHARMACEUTICALS v. ELI LILLY (Fed. Cir. 2010 en banc): wrote description is a separate requirement from enablement; describes the test: whether the specification reasonably conveys to persons skilled in the art that the inventor had possession of the claimed subject matter as of the filing date; REPRESENTATIVE SPECIES: for genus claims, courts look for: (a) representative number of species spanning the full scope of the genus; (b) common structural features that correlate with the claimed function; (c) a description of the genus that distinguishes it from the prior art; REGENTS OF UC v. ELI LILLY (Fed. Cir. 1997): genus claims to nucleic acids (cDNA) encoding a protein were insufficient — disclosing only the human sequence didn't provide written description support for the full mammalian genus; CORRELATION BETWEEN STRUCTURE AND FUNCTION: if a genus claim is defined functionally, the specification must show a structure-function relationship that allows a POSITA to predict which structures have the claimed function; WRITTEN DESCRIPTION vs. ENABLEMENT: written description asks 'did the inventor possess this?'; enablement asks 'can a POSITA make and use this?'; both can independently invalidate a genus claim; both were at issue in Amgen v. Sanofi (the court decided on enablement but noted written description concerns).

After Amgen v. Sanofi (S.Ct. 2023), applicants in pharma and biotech must rethink genus claiming strategy: STRATEGY 1 — STRUCTURAL DEFINITION OF GENUS: define the genus by structure (specific chemical formula, amino acid sequence motifs, core scaffold) rather than function alone; structural genus claims require fewer working examples to enable; 'a compound of formula [Markush group]' is more defensible than 'any compound that inhibits [function]'; STRATEGY 2 — MAXIMIZE WORKING EXAMPLES: the more working examples disclosed across the full scope of the claimed genus, the stronger the enablement case; disclose examples from multiple subgenera; Amgen's mistake: only 26 examples for a genus of potentially millions; STRATEGY 3 — DISCLOSE A PREDICTIVE STRUCTURE-FUNCTION RELATIONSHIP: if the genus is defined functionally, provide a structural explanation of WHY certain structures have the function; this allows a POSITA to predict which structures will work without undue experimentation; STRATEGY 4 — CLAIM SUBGENERA SEPARATELY: break the full genus into smaller, better-supported subgenera; if Subgenus A is fully enabled, claim Subgenus A even if the full genus is not; dependent claims and continuation claims can cover additional subgenera as research progresses; STRATEGY 5 — CONTINUATION PRACTICE: file continuation applications as new species are discovered; each continuation can claim a newly discovered species as a specific narrow claim (easily enabled); build a family with both broad genus claims (possibly vulnerable) and specific species claims (easier to enforce); STRATEGY 6 — PROVISIONAL APPLICATION DISCLOSURE: file provisional applications early with maximum working examples; add examples before the non-provisional filing date; the key is the filing date content — what was in the specification at filing governs enablement and written description.

Genus claims are the primary battleground in pharmaceutical and biotech patent litigation: PHARMACEUTICAL USE: drug companies draft genus claims covering entire chemical series — e.g., 'a compound of formula [core scaffold]-[variable side chain]'; when a competitor's drug has the same core scaffold with a different side chain, the genus claim covers it; this is how pioneers in a drug class try to maintain market exclusivity across the entire class; CHALLENGE — DESIGN AROUND: a competitor must find a compound outside the genus (different core scaffold) that achieves the same therapeutic result; designing around a well-drafted genus claim often requires finding a structurally unrelated compound; CHALLENGE — GENUS VALIDITY (POST-AMGEN): after Amgen, broad functional genus claims are highly vulnerable to invalidity challenges on enablement and written description grounds; IPR LIMITATION: IPR is limited to § 102 and § 103 prior art challenges; § 112 enablement/written description challenges to genus claims must be brought in district court or PGR (within 9 months of grant); HATCH-WAXMAN PARAGRAPH IV: generic pharmaceutical challengers file Paragraph IV certifications asserting that the genus claim patent is invalid (typically for obviousness or lack of written description); this triggers litigation that delays the generic's market entry; BIOSIMILAR CONTEXT: biologics (monoclonal antibodies, biologics) have genus claims for classes of antibodies; after Amgen, these are now highly vulnerable; biosimilar applicants challenge genus claims in district court invalidity proceedings; FEDERAL CIRCUIT TREND: the Federal Circuit has been increasingly skeptical of broad functional genus claims since 2010; Amgen (S.Ct.) provides the latest and most authoritative statement of the enablement standard; expect more genus claim invalidations in future litigation.